Long-term reduction of C-reactive protein concentration by regular LDL apheresis

Atherosclerosis

Volumn 174, Issue 1, 2004, Pages 151-156

  Otto, Carsten ^a   Geiss, H Christian ^a   Empen, Klaus ^a,b   Parhofer, Klaus G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

C reactive protein; Fibrinogen; Hypercholesterolemia; LDL apheresis; LDL cholesterol

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; COLESTIPOL; COLESTYRAMINE; DEXTRAN SULFATE; FENOFIBRATE; FIBRINOGEN; HEPARIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; SITOSTEROL;

ADULT; APHERESIS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOADSORPTION; IMMUNOPRECIPITATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PRIORITY JOURNAL;

ADULT; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PLASMAPHERESIS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 2342460220     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.01.017     Document Type: Conference Paper

References (20)

1. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979
2. Haverkate F., Thompson S.G., Pyke S.D.M., Gallimore J.R., Pepys M.B. for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466
3. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-116
4. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168
5. Otto C., Schwandt P. C-reactive protein concentration is reduced by different types of LDL apheresis. Atherosclerosis Suppl. 2:2001;81-82
6. Wieland E., Schettler V., Armstrong V.W. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low-density lipoprotein apheresis. Atherosclerosis. 162:2002;187-191
7. Moriarty P.M., Gibson C.A., Shih J., Matias M.S. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis. 158:2001;495-498
8. Dräger L.J., Julius U., Kraenzle K., et al. DALI - the first human whole blood LDL and Lp(a) apheresis system in clinical use: procedure and clinical results. Eur. J. Clin. Invest. 28:1998;994-1002
9. Richter W.O., Donner M.G., Schwandt P. Short- and long-term effects on serum lipoproteins by three different techniques of apheresis. Artif. Organs. 20:1996;311-317
10. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. 45:1999;2136-2141
11. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifugation. Clin. Chem. 18:1972;499-502
12. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 97:1998;2007-2011
13. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347:2002;1557-1565
14. Schuff-Werner P., Gohlke H., Bartmann U., et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur. J. Clin. Invest. 24:1994;724-732
15. Kroon A.A., Aengevaeren W.R., van der Werf T., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835
16. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82:1998;1489-1495
17. Hutchinson W.L., Koenig W., Fröhlich M., Sund M., Lowe G.D.O. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem. 46:2000;934-938
18. Kojima S., Shida M., Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther. Apheresis. 7:2003;431-434
19. Li J.J., Chen M.Z., Chen X., Fang C.H. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin. Cardiol. 26:2003;472-476
20. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J. Am. Med. Assoc. 279:1998;1477-1482